Koca Dogan, Oztop Ilhan, Yavuzsen Tugba, Ellidokuz Hulya, Yilmaz Ugur
Dokuz Eylul University, Department of Internal Diseases, Izmir, Turkey.
Asian Pac J Cancer Prev. 2011;12(12):3181-6.
To evaluate the efficacy of modified De Gramont (mDG) and FOLFOX4 (mFOLFOX4) regimens in patients with locally advanced rectal cancer (LARC).
Patients that received adjuvant chemotherapy (CT) for the treatment of LARC (stage II and III) were retrospectively evaluated.
A total of 231 patients were examined. Median age was 58 (range, 18-83) and, of these patients, 36 (15.6%) had stage II and 195 (84.4%) had stage III disease. While the patients with stage II disease received only mDG regimen (36, 100.0%), of the patients with stage III disease, 71 (36.5%) received mDG and 124 (63.5%) received mFOLFOX4 regimen. Patients with stage III disease showed recurrences more often, but this difference was not statistically significant. Similarly, for the patients with stage III disease, there was no statistically significant relation between the adjuvant CT regimen received and the rate of recurrence. In patients with stage II disease, who received mDG, median DFS was 101 months and median OS was 106 months. For the patients with stage III disease, the patients that received mDG showed a median DFS of 78 months and a median OS of 96 months, while the patients that received mFOLFOX4 had a median DFS of 51 months and a median OS of 78 months. Although, for the patients with stage III disease, there are major differences between the two different regimens of CT in terms of DFS and OS, this difference was not statistically significant.When the results were evaluated from the perspective of toxicity, the patients that received mFOLFOX4 showed more toxicity. Neurotoxicity, which was seen in the patients that were given mFOLFOX4, was the most prominent toxicity.
mDG and mFOLFOX4 regimens are applicable regimens as adjuvant CT for the treatment of LARC.
评估改良德格拉蒙（mDG）和FOLFOX4（mFOLFOX4）方案治疗局部晚期直肠癌（LARC）患者的疗效。
对接受辅助化疗（CT）治疗LARC（II期和III期）的患者进行回顾性评估。
共检查了231例患者。中位年龄为58岁（范围18 - 83岁），其中36例（15.6%）为II期疾病，195例（84.4%）为III期疾病。II期疾病患者仅接受mDG方案（36例，100.0%），III期疾病患者中，71例（36.5%）接受mDG方案，124例（63.5%）接受mFOLFOX4方案。III期疾病患者复发更常见，但这种差异无统计学意义。同样，对于III期疾病患者，接受的辅助CT方案与复发率之间无统计学显著关系。在接受mDG的II期疾病患者中，中位无病生存期（DFS）为101个月，中位总生存期（OS）为106个月。对于III期疾病患者，接受mDG方案的患者中位DFS为78个月，中位OS为96个月，而接受mFOLFOX4方案的患者中位DFS为51个月，中位OS为78个月。虽然对于III期疾病患者，两种不同CT方案在DFS和OS方面存在较大差异，但这种差异无统计学意义。从毒性角度评估结果时，接受mFOLFOX4方案的患者毒性更大。接受mFOLFOX4方案的患者出现的神经毒性是最突出的毒性。
mDG和mFOLFOX4方案作为LARC辅助CT治疗的适用方案。
